Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2010 Jul;12(7):756-62.
doi: 10.1093/ntr/ntq078. Epub 2010 May 26.

Do point prevalence and prolonged abstinence measures produce similar results in smoking cessation studies? A systematic review

Affiliations
Comparative Study

Do point prevalence and prolonged abstinence measures produce similar results in smoking cessation studies? A systematic review

John R Hughes et al. Nicotine Tob Res. 2010 Jul.

Abstract

Introduction: Many smoking cessation trials report either prolonged abstinence (PA) rates (i.e., not smoking since a quit date, with or without a grace period) or point prevalence (PP) abstinence rates (i.e., no smoking one or more days prior to the follow-up), but how these two relate is unclear.

Methods: We located 28 pharmacotherapy trials that provided 76 within-study comparisons of PA versus PP. The first two authors independently coded all trials.

Results: The two measures were highly correlated (r = .88) and PA averaged 0.74 that of PP. Equations for converting PP to PA and vice versa produced estimations that, in 90% of cases, were within 4%-5% of actual PP or PA values. The odds ratio and the relative risk for active versus control were identical when PA and PP were used; however, the difference in proportion abstinent for active versus control was somewhat less when PA was used than when PP was used (8% vs. 10%).

Discussion: We conclude that PA and PP are closely related and can be interconverted with moderate accuracy. They also produce similar effect sizes when odds ratio and relative risk are used as effect sizes. When absolute difference in percent abstinent is used as an effect size, PA produces a smaller effect size than PP. We believe trials should continue to report both PA and PP outcomes to enhance comparisons across studies.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Correlation between point prevalence (PP) and prolonged abstinence (PA) across all 76 comparisons. The solid line represents values expected if PP = PA. The dotted line is the regression line of best fit for PP versus PA.

References

    1. Balk EM, Bonis PAL, Moskowitz H, Schmid CH, Ioannidis JPA, Wang C, et al. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. Journal of the American Medical Association. 2002;287:2973–2982. - PubMed
    1. Fagerstrom K, Hughes JR. Varenicline in the treatment of tobacco. Neuropsychiatric Disease and Treatment. 2008;4:1–11. - PMC - PubMed
    1. Fiore M, Jaen C, Baker T, Bailey W, Benowitz N, Curry S, et al. Treating tobacco use and dependence: Clinical practice guideline. Washington, DC: US Public Health and Human Services; 2008.
    1. Fiore MC, Smith SS, Jorenby DE, Baker TB. The effectiveness of the nicotine patch for smoking cessation: A meta-analysis. Journal of the American Medical Association. 1994;271:1940–1946. - PubMed
    1. Fisher KJ, Glasgow RE, Terborg JR. Worksite smoking cessation: A meta-analysis of long-term quit rates from controlled studies. Journal of Occupational Medicine. 1990;32:429–439. - PubMed

Appendix Studies used in the meta-analysis

    1. Ahluwalia JS, Harris KJ, Catley D, Okuyemi KS, Mayo MS. Sustained-release bupropion for smoking cessation in African Americans. A randomized controlled trial. Journal of the American Medical Association. 2002;288:468–474. - PubMed
    1. Aubin HJ, Lebargy F, Berlin I, Bidaut-Mazel C, Chemali-Hudry J, Lagrue G. Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: A randomized placebo-controlled trial. Addiction. 2004;99:1206–1218. - PubMed
    1. Blondal T. Controlled trial of nicotine polacrilex gum with supportive measures. Archives of Internal Medicine. 1989;149:1818–1821. - PubMed
    1. Brown R, Niaura R, Lloyd-Richardson E, Strong D, Kahler C, Abrantes A, et al. Bupropion and cognitive-behavioral treatment for depression in smoking cessation. Nicotine & Tobacco Research. 2007;9:721–730. - PMC - PubMed
    1. Fossati R, Apolone G, Negri E, Compagnoni A, La Vecchia C, Mangano S, et al. A double-blind, placebo-controlled, randomized trial of bupropion for smoking cessation in primary care. Archives of Internal Medicine. 2007;167:1791–1797. - PubMed

Publication types

MeSH terms